분자진단 시장 보고서 : 제품별, 기술별, 용도별, 최종사용자별, 지역별(2026-2034년)

The global molecular diagnostics market size reached USD 22.1 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 36.3 Billion by 2034, exhibiting a growth rate (CAGR) of 5.52% during 2026-2034. The increasing prevalence of infectious diseases and genetic disorders, technological advancements in polymerase chain reaction (PCR), growing aging population, surging awareness of early disease detection, and supportive government initiatives are factors shaping the market's trajectory.

Molecular Diagnostics Market Analysis:

Major Market Drivers: The market for molecular diagnostics is expanding primarily due to rise in chronic and infectious illnesses which in turn is leading to growing demand for accurate diagnostics methods. In addition, the continual advancements in genomic and personalized medicine are contributing to the molecular diagnostics market growth.

Key Market Trends: Substantial trends include the demand for PCR as it is accurate and fast and the increase in reagents and kits due to the new methodologies and diagnostic technologies. Besides, the movement towards non-invasive, early diagnosis approaches is also supporting the demand.

Geographical Trends: North America is the leader in the world, due to the presence of advanced medical infrastructure, more investments in R&D and a great emphasis on personalized medicine. In addition, Asia-Pacific faces a fast development through increasing resource usage and more health-related knowledge and spendings.

Competitive Landscape: The key competitive companies that are constantly contributing to the market are Roche Diagnostics, Abbott Laboratories, QIAGEN, Bio-Rad Laboratories, Siemens Healthineers, and Thermo Fisher Scientific and others. These enterprises invest heavily in the new technologies and partnerships to maintain the molecular diagnostics market share and occupy new territories.

Challenges and Opportunities: The barriers are regulatory intricacies and finances of the molecular diagnostics. Along with the challenges, new opportunities emerge for healthcare providers from the growing healthcare needs in the emerging markets and from the constant technological advances which promise better diagnostics and expand the market.

Molecular Diagnostics Market Trends:

Increasing prevalence of chronic and infectious diseases

The market is exhibiting an outstanding growth rate which is mainly due to the increasing cases of acute and chronic illnesses. This increase in disease occurrence, including cancer, heart diseases, and infection focuses on the significant role of the molecular diagnostics in giving fast and proper diagnosis of the disease. This attribute enables the better patient outcomes and also constitutes individual response personalized treatment plans, which increases the molecular diagnostics demand in the market. Along with the expanding complexities of health conditions all over the world, the demand for newfangled molecular diagnostic equipment is rising, which in turn perpetuates the market growth. According to a report by the ministry of health, in 2016, non-communicable diseases (NCDs) accounted for 61% of all mortalities and 55% of disability cases.

Technological advancements in genomics and personalized medicine

The sector is experiencing developments in genomics and personalized medicine that are crucial for the global molecular diagnostics market trends. Genetic profiling innovations for DNA sequencing, gene expression, and next-generation DNA sequencing such as RNA are essential and changing the ways of diagnosis and allowing the identification of specific disease markers and genetic predispositions. The utilization of personalized medicine, which entails to tailoring treatment based on the individual's genetic profile, is creating a need for sophisticated diagnostic technologies, that is able to decipher complex genetic information accurately. The rising cooperation between sophisticated technologies and tailored treatments is expanding the market share.

According to the personalized medicine report, in 2015, U.S. President Barack Obama launched the precision medicine initiative (PMI). This initiative offers researchers secure access to an extensive array of genomic data, starting with thousands and potentially expanding to one million genome sequences, for in-depth scientific research.

Rising aging population and demand for targeted diagnostics

The demand for efficient diagnostic method is rising due to rising illnesses, such as neurodegenerative disorders and cardiovascular problems in geriatric populations. Molecular diagnostics offer a valuable functionality of early detection of health conditions, thus providing a clear path for treatment at convenient and improved outcomes. The growing trend of this demographic is significantly increasing demand for non-invasive and accurate tools such as lab-on-a-chip (LOA) technology which is indicative of an increasing market segment's inclination to adapt to this new health requirement. This population shift is a significant contributing to the molecular diagnostics market analysis.

Molecular Diagnostics Market Segmentation:

This report provides an analysis of the key trends in each segment of the global molecular diagnostics market report, along with forecasts at the global, regional, and country levels for 2026-2034. The report categorizes the market based on product, technology, application, and end users.

Breakup by Product:

• Reagents and Kits
• Instruments
• Software and Services

Reagents and kits dominate the market

The market is experiencing a significant increase, particularly in the reagents and kits segment, due to the expansion of molecular diagnostics reach into various medical areas of specialization. Fresh paradigms in research and novel inventions generate novel assays and testing methods that require the appropriate reagents and kits to be feasible. The growing number of chronic diseases make the need for fast and dependable diagnostic tools more crucial, driving the increase. Involvement of the major companies with research institutions also has an impact on the development of new reagents and kits, and hence plays a significant part in increasing the molecular diagnostics market revenue.

Breakup by Technology:

• Polymerase Chain Reactions (PCR)
• Hybridization
• DNA Sequencing
• Microarray
• Isothermal Nucleic Acid Amplification Technology (INAAT)
• Others

Polymerase chain reactions (PCR) dominate the market

The PCR segment is dominating the molecular diagnostics market outlook. The advent of PCR technology refinements, including the designing and constructing of qPCR and dPCR, propel the amplification's biochemical process, thereby improves the sensitivity, accuracy, and speed. Such advancement of PCR has made it an indispensable instrument in molecular diagnostics. Precise analysis of genetic profiles which can be used in personalized medicine and targeted therapies is now essential to these treatments. Besides, the point-of-care diagnostics advancement and PCR platform introduction into both of the healthcare professionals and patients make molecular testing more available this leads broaden its integration among healthcare environments.

Breakup by Application:

• Infectious Diseases Diagnostics
• Oncology
• Genetic Testing
• Blood Screening
• Others

Infectious diseases diagnostics dominate the market

The molecular diagnostics market overview explains that the market dynamics are in line with rapid spread of infectious diseases, encompassing viral, bacterial, and fungal infections. The rapid spread of diseases, especially those which have the potential to plunge the world into pandemics, has caused an urgent need for early detection mechanism and the use of viable containment strategies. The advent of molecular biology and immunoassay technologies in diagnostics revolutionized this landscape by enhancing the accuracy and speed of pathogen detection and typing for their resistances. This breakthrough has led to the creation of a promising market for molecular diagnostics and indicates a strong trend of the growth of preventive health and surveillance projects. These measures play an important role in the medical involvement and stopping the spread of infections.

Breakup by End Users:

• Hospitals
• Laboratories
• Others

Breakup by Region:

• North America
• United States
• Canada
• Asia-Pacific
• China
• Japan
• India
• South Korea
• Australia
• Indonesia
• Others
• Europe
• Germany
• France
• United Kingdom
• Italy
• Spain
• Russia
• Others
• Latin America
• Brazil
• Mexico
• Others
• Middle East and Africa

North America exhibits a clear dominance, accounting for the largest molecular diagnostics market share

The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America represents the largest regional market for molecular diagnostics.

North America market is growing due to the strong culture of perpetual research and development innovation, as per the molecular diagnostics market forecast period. With the increase in the development of chronic diseases, such as cancer, cardiovascular diseases and diabetes, the rapid and reliable detection methods are required. The increased level of personalized medicine understanding in healthcare professionals and patients alongside other factors is propelling the market growth. Development of government aid in the healthcare modernization and the establishment of molecular diagnostics techniques are the major economies drivers in the business growth. Furthermore, DTC genetic testing is also a significant part which improves the level of consumer interaction and supports the molecular diagnostics market recent opportunities.

Competitive Landscape:

The report has provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

• Abbott Laboratories
• Agilent Technologies Inc.
• Becton Dickinson and Company
• Biomerieux SA
• Danaher Corporation
• Diasorin Molecular LLC (DiaSorin)
• F. Hoffmann-La Roche AG (Roche Holding AG)
• Hologic Inc.
• Illumina Inc.
• Myriad Genetics Inc.
• Qiagen
• Quidel Corporation
• Thermo Fisher Scientific

Key Questions Answered in This Report

1. How big is the molecular diagnostics market?

2. What is the future outlook of molecular diagnostics market?

3. What are the key factors driving the molecular diagnostics market?

4. Which region accounts for the largest molecular diagnostics market share?

5. Which are the leading companies in the global molecular diagnostics market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Molecular Diagnostics Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Product

• 6.1 Reagents and Kits
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Instruments
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast
• 6.3 Software and Services
  • 6.3.1 Market Trends
  • 6.3.2 Market Forecast

7 Market Breakup by Technology

• 7.1 Polymerase Chain Reactions (PCR)
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Hybridization
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 DNA Sequencing
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast
• 7.4 Microarray
  • 7.4.1 Market Trends
  • 7.4.2 Market Forecast
• 7.5 Isothermal Nucleic Acid Amplification Technology (INAAT)
  • 7.5.1 Market Trends
  • 7.5.2 Market Forecast
• 7.6 Others
  • 7.6.1 Market Trends
  • 7.6.2 Market Forecast

8 Market Breakup by Application

• 8.1 Infectious Diseases Diagnostics
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Oncology
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Genetic Testing
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast
• 8.4 Blood Screening
  • 8.4.1 Market Trends
  • 8.4.2 Market Forecast
• 8.5 Others
  • 8.5.1 Market Trends
  • 8.5.2 Market Forecast

9 Market Breakup by End Users

• 9.1 Hospitals
  • 9.1.1 Market Trends
  • 9.1.2 Market Forecast
• 9.2 Laboratories
  • 9.2.1 Market Trends
  • 9.2.2 Market Forecast
• 9.3 Others
  • 9.3.1 Market Trends
  • 9.3.2 Market Forecast

10 Market Breakup by Region

• 10.1 North America
  • 10.1.1 United States
    • 10.1.1.1 Market Trends
    • 10.1.1.2 Market Forecast
  • 10.1.2 Canada
    • 10.1.2.1 Market Trends
    • 10.1.2.2 Market Forecast
• 10.2 Asia-Pacific
  • 10.2.1 China
    • 10.2.1.1 Market Trends
    • 10.2.1.2 Market Forecast
  • 10.2.2 Japan
    • 10.2.2.1 Market Trends
    • 10.2.2.2 Market Forecast
  • 10.2.3 India
    • 10.2.3.1 Market Trends
    • 10.2.3.2 Market Forecast
  • 10.2.4 South Korea
    • 10.2.4.1 Market Trends
    • 10.2.4.2 Market Forecast
  • 10.2.5 Australia
    • 10.2.5.1 Market Trends
    • 10.2.5.2 Market Forecast
  • 10.2.6 Indonesia
    • 10.2.6.1 Market Trends
    • 10.2.6.2 Market Forecast
  • 10.2.7 Others
    • 10.2.7.1 Market Trends
    • 10.2.7.2 Market Forecast
• 10.3 Europe
  • 10.3.1 Germany
    • 10.3.1.1 Market Trends
    • 10.3.1.2 Market Forecast
  • 10.3.2 France
    • 10.3.2.1 Market Trends
    • 10.3.2.2 Market Forecast
  • 10.3.3 United Kingdom
    • 10.3.3.1 Market Trends
    • 10.3.3.2 Market Forecast
  • 10.3.4 Italy
    • 10.3.4.1 Market Trends
    • 10.3.4.2 Market Forecast
  • 10.3.5 Spain
    • 10.3.5.1 Market Trends
    • 10.3.5.2 Market Forecast
  • 10.3.6 Russia
    • 10.3.6.1 Market Trends
    • 10.3.6.2 Market Forecast
  • 10.3.7 Others
    • 10.3.7.1 Market Trends
    • 10.3.7.2 Market Forecast
• 10.4 Latin America
  • 10.4.1 Brazil
    • 10.4.1.1 Market Trends
    • 10.4.1.2 Market Forecast
  • 10.4.2 Mexico
    • 10.4.2.1 Market Trends
    • 10.4.2.2 Market Forecast
  • 10.4.3 Others
    • 10.4.3.1 Market Trends
    • 10.4.3.2 Market Forecast
• 10.5 Middle East and Africa
  • 10.5.1 Market Trends
  • 10.5.2 Market Breakup by Country
  • 10.5.3 Market Forecast

11 SWOT Analysis

• 11.1 Overview
• 11.2 Strengths
• 11.3 Weaknesses
• 11.4 Opportunities
• 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

• 13.1 Overview
• 13.2 Bargaining Power of Buyers
• 13.3 Bargaining Power of Suppliers
• 13.4 Degree of Competition
• 13.5 Threat of New Entrants
• 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

• 15.1 Market Structure
• 15.2 Key Players
• 15.3 Profiles of Key Players
  • 15.3.1 Abbott Laboratories
    • 15.3.1.1 Company Overview
    • 15.3.1.2 Product Portfolio
    • 15.3.1.3 Financials
    • 15.3.1.4 SWOT Analysis
  • 15.3.2 Agilent Technologies Inc.
    • 15.3.2.1 Company Overview
    • 15.3.2.2 Product Portfolio
    • 15.3.2.3 Financials
    • 15.3.2.4 SWOT Analysis
  • 15.3.3 Becton Dickinson and Company
    • 15.3.3.1 Company Overview
    • 15.3.3.2 Product Portfolio
    • 15.3.3.3 Financials
    • 15.3.3.4 SWOT Analysis
  • 15.3.4 Biomerieux SA
    • 15.3.4.1 Company Overview
    • 15.3.4.2 Product Portfolio
    • 15.3.4.3 Financials
    • 15.3.4.4 SWOT Analysis
  • 15.3.5 Danaher Corporation
    • 15.3.5.1 Company Overview
    • 15.3.5.2 Product Portfolio
    • 15.3.5.3 Financials
    • 15.3.5.4 SWOT Analysis
  • 15.3.6 Diasorin Molecular LLC (DiaSorin S.p.A.)
    • 15.3.6.1 Company Overview
    • 15.3.6.2 Product Portfolio
  • 15.3.7 F. Hoffmann-La Roche AG (Roche Holding AG)
    • 15.3.7.1 Company Overview
    • 15.3.7.2 Product Portfolio
    • 15.3.7.3 SWOT Analysis
  • 15.3.8 Hologic Inc.
    • 15.3.8.1 Company Overview
    • 15.3.8.2 Product Portfolio
    • 15.3.8.3 Financials
    • 15.3.8.4 SWOT Analysis
  • 15.3.9 Illumina Inc.
    • 15.3.9.1 Company Overview
    • 15.3.9.2 Product Portfolio
    • 15.3.9.3 Financials
    • 15.3.9.4 SWOT Analysis
  • 15.3.10 Myriad Genetics Inc.
    • 15.3.10.1 Company Overview
    • 15.3.10.2 Product Portfolio
    • 15.3.10.3 Financials
    • 15.3.10.4 SWOT Analysis
  • 15.3.11 Qiagen
    • 15.3.11.1 Company Overview
    • 15.3.11.2 Product Portfolio
    • 15.3.11.3 Financials
    • 15.3.11.4 SWOT Analysis
  • 15.3.12 Quidel Corporation
    • 15.3.12.1 Company Overview
    • 15.3.12.2 Product Portfolio
    • 15.3.12.3 Financials
    • 15.3.12.4 SWOT Analysis
  • 15.3.13 Thermo Fisher Scientific
    • 15.3.13.1 Company Overview
    • 15.3.13.2 Product Portfolio
    • 15.3.13.3 Financials
    • 15.3.13.4 SWOT Analysis